Welcome to our dedicated page for Perspective Therapeutics news (Ticker: CATX), a resource for investors and traders seeking the latest updates and insights on Perspective Therapeutics stock.
Perspective Therapeutics develops radiopharmaceutical candidates for cancer using proprietary Lead-212 (212Pb) technology and specialized targeting moieties. Its updates center on a theranostic approach that pairs targeted alpha therapy with complementary imaging diagnostics.
Recurring CATX news covers clinical and conference updates for VMT-α-NET in SSTR2-expressing neuroendocrine tumors, VMT01 for melanoma, and PSV359 for solid tumors, along with business results, financing activity, manufacturing infrastructure, 212Pb generator-enabled finishing facilities, and corporate presentations.
Perspective Therapeutics (NYSE AMERICAN: CATX) provided clinical and operational updates ahead of its J.P. Morgan presentation on January 14, 2026 at 2:15 p.m. PT. Key points: updated [212Pb]VMT-α-NET data (DCO Dec 10, 2025) show no DLTs in a 56-patient safety set and durable disease control in an efficacy subset (19/25 without progression). Cohort 3 DLT assessment is complete and enrollment continues. VMT01 and PSV359 remain in early dose-finding stages with additional clinical readouts expected mid–late 2026. Manufacturing capacity expansion is underway.
Perspective Therapeutics (NYSE:CATX) reported updated interim Phase 1/2a data for [212Pb]VMT-α-NET with a data cut-off of December 10, 2025. Safety analysis covered 56 patients across three dose cohorts (2.5, 5.0, 6.0 mCi) with no DLTs, no treatment-related discontinuations, and no Grade 5 events; Grade ≥3 events occurred in 21 patients (37.5%) and one transient Grade 4 lymphopenia resolved. Efficacy analysis in 25 patients (2 in Cohort 1; 23 in Cohort 2) showed 9/23 (39%) objective responses in Cohort 2 (8 confirmed previously) and 19/25 (76%) without progression and alive at update. Cohort 3 DLT assessment completed and additional enrollment cleared.
Perspective Therapeutics (NYSE American: CATX) announced that CEO Thijs Spoor will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026.
The company presentation is scheduled for 2:15–2:55 p.m. PT at The Westin St. Francis Hotel and will cover Perspective's radiopharmaceutical development programs targeting cancers throughout the body.
Perspective Therapeutics (NYSE AMERICAN: CATX) announced that updated data for its [212Pb]VMT-α-NET program were accepted for presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) Congress 2026.
The accepted poster, presented by Thorvardur Halfdanarson from Mayo Clinic Comprehensive Cancer Center, covers safety and preliminary efficacy results in advanced SSTR2-expressing neuroendocrine tumors. The poster is Abstract No. 635 in the session "Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract" and will be shown on January 9, 2026 at two times: 11:30 am–1:00 pm PT and 5:00–6:00 pm PT. ASCO-GI will release full regular-abstract details on January 5, 2026.
Perspective Therapeutics (NYSE AMERICAN: CATX) said senior leadership will participate in two investor conferences in early December 2025.
Events: Piper Sandler 37th Annual Healthcare Conference fireside chat on Dec 2, 2025 at 1:00–1:25 p.m. ET in New York, and Evercore 8th Annual Healthcare Conference fireside chat on Dec 3, 2025 at 3:00–3:20 p.m. ET in Miami. Management will also be available for one-on-one investor meetings.
Perspective Therapeutics (NYSE AMERICAN: CATX) reported 3Q 2025 results and a business update on Nov 10, 2025, highlighting clinical progress and balance sheet status.
Key clinical points: updated interim [212Pb]VMT-α-NET data (DCO Sep 12, 2025) showed favorable safety in 55 treated patients with no DLTs or Grade 4–5 TEAEs and investigator-assessed responses in Cohort 2; Cohort 3 (6.0 mCi) opened June 2025 with eight patients dosed. VMT01 and PSV359 continue early-stage dosing and site activations.
Financials: cash and short-term investments ~$174M at Sep 30, 2025, expected to fund operations into late 2026; R&D and operating expenses rose materially year‑over‑year, driving a wider net loss.
Perspective Therapeutics (NYSE AMERICAN: CATX) said senior leadership will attend investor meetings at two November 2025 conferences.
Meetings include one-on-one meetings at the Truist Securities BioPharma Symposium on Thursday, November 6, 2025 in New York, and a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 11, 2025 from 4:15–4:50 p.m. ET in Palm Beach, Florida.
Perspective Therapeutics (NYSE AMERICAN: CATX) will report its third quarter 2025 financial results and provide a business update on Monday, November 10, 2025 after the market closes.
The company said the related press release will be published on its newsroom at https://perspectivetherapeutics.com/newsroom/press-releases.
Perspective Therapeutics (NYSE: CATX) reported updated interim Phase 1/2a results for [212Pb]VMT-α-NET with a data cut-off of Sept 12, 2025, presented at ESMO 2025.
Key findings: 55 patients received at least one dose; no dose limiting toxicities or treatment-related discontinuations; Objective Response Rate 44% (7/16) in Cohort 2 patients with SSTR2 expression in all tumors at a median follow-up of 41 weeks; 14 of 16 such patients (87.5%) were progression-free and on study. Additional interim efficacy data for 23 Cohort 2 and 8 Cohort 3 patients are expected in 2026. Preliminary cash was $174.1M as of Sept 30, 2025, projected to fund operations into late 2026. A webcasted conference call was held on Oct 20, 2025 at 8:30 AM ET.
Perspective Therapeutics (NYSE AMERICAN: CATX) has announced the dosing of the first patient in the second cohort of its Phase 1/2a clinical trial for [212Pb]PSV359. The study is evaluating the safety and preliminary anti-tumor activity in patients with FAP-α positive solid tumors.
The second cohort patients will receive 5.0 mCi of [212Pb]PSV359 for up to four doses every eight weeks, an increase from the 2.5 mCi dose in the first cohort. The dose escalation was recommended by the Safety Monitoring Committee following their review of two patients from the initial cohort.
Patient selection is conducted through SPECT imaging with [203Pb]PSV359. The treatment targets FAP-α, which is present in various epithelial malignancies including pancreatic cancer, colorectal cancer, and sarcomas.